Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

 
• By Alaric DeArment

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Editorial use only - ARCADIA, CA - MAR 20: Horses break from the gate in an allowance race at Santa Anita Park on Mar 20, 2010 in Arcadia, CA
Mustang Bio announced data from the Phase I/II study of the anti-CD20 CAR-T therapy MB-106 in B-cell malignancies • Source: Shutterstock

More from Immuno-oncology

More from Anticancer